Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
April 26, 2024
*Biodexa Pharmaceuticals PLC*
(“Biodexa” or the “Company”)
*Biodexa Enters Into..